摘要
目的研究阿奇霉素联合热毒宁治疗小儿支原体肺炎的疗效及安全性,为临床合理应用抗菌药物提供参考。方法采用随机对照方法将2010年3月至2012年1月入我院治疗的支原体肺炎患儿164例进行研究,随机分为治疗组和对照组各82。治疗组患儿应用阿齐霉素加热毒宁静脉滴注,疗程5~10 d;对照组患儿单用阿奇霉素静脉滴注,疗程7~13 d。结果治疗组总有效率为98.86%,对照组治疗总有效率为89.77%,2组比较差异有统计学意义(P<0.05);治疗组患儿退热时间、咳嗽好转时间、啰音消失时间、平均治愈时间均较对照组短,差异有统计学意义(P<0.05);胃肠道反应、皮疹、ALT增高等不良反应,二者相比差异无统计学意义(P>0.05)。结论阿奇霉素联合热毒宁治疗小儿支原体肺炎临床疗效显著,临床症状消失更迅速,不良反应少,好于阿奇霉素单一治疗,值得临床推广应用。
Objective To study the efficacy and safety of azithromycin plus Reduning in the treatment of mycoplasma pneumonia in children, and thus provide a reference for the clinical rational use of antibacterial drugs. Methods One hundred and sixty-four children with mycoplasma pneumonia from March 2010 to Januar- y 2012 were divided randomly into treatment group and control group, with 82 cases per group. The treatment group was treated with azithromycine plus Reduning intravenous injection for 5 to 10 days and the control group was treated with azithromycine intravenous injection for 7 to 13 days. Results Efficacy rate of treatment group and control group was 98.86% and 89.77 respectively. There was a significant difference in clinical efficacy between the treatment group and the control group ( P 〈 0.05 ). The pyretolysis time, cough improvement time, tale disappearing time and the mean time of healing well of treatment group were shorter than that of control group, and the difference was remarkable ( P 〈 0. 05 ). There was no significant difference in adverse reaction of gastrointestinal reactions, rash, ALT increased, etc. (P 〉 0. 05 ). Conclusion Azithromycin plus Reduning is more effective and safer in treatment of mycoplasma pneumonia in children than Azithromycin single used, and it deserves to be applied in the clinic.
出处
《中国实用医药》
2012年第16期28-29,共2页
China Practical Medicine
关键词
阿奇霉素
热毒宁
支原体肺炎
Azithromycin
Reduning
Mycoplasma pneumonia